Respironics ( RESP - NASDAQ ) has just reported the last Q results . Part of RESPIRONICS biz is actually the second leg in the DUOPOLY of RMD/RESP in the APNEA sleep disorder market . Key drivers for the Company's domestic revenue performance include a year-over-year increase of 15 percent in domestic sleep therapy products. Let's hope RMD did the same . First call consensus expected increase for RMD is 12% in EPS growth .It is expected to report EPS USc 28 for the Q and USD 1.06 for the FY , Duff
RMD - A possible profit clue
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$27.49 |
Change
0.120(0.44%) |
Mkt cap ! $43.01B | |||
| Open | High | Low | Value | Volume |
| $27.68 | $27.70 | $27.47 | $12.66M | 459.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 4644 | $27.48 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $27.53 | 31506 | 1 |
View Market Depth
| Last trade - 16.10pm 19/01/2021 (20 minute delay) ? |
 (live)
|
|||||
|
Last
$27.57 |
Change
0.120 ( 0.55 %) |
||||
| Open | High | Low | Volume | ||
| $27.63 | $27.70 | $27.50 | 76048 | ||
| Last updated 15.59pm 19/01/2021 (live) ? | |||||
| RMD (ASX) Chart |